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Background/Aims
Opioid induced bowel dysfunction (OIBD) is associated with decreased gastrointestinal (GI) propulsive activity due to intake of opioid 
analgesics. DA-9701, a novel prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber has promising effects on GI motor 
function. Therefore, we aim to evaluate the prokinetic effects of DA-9701 in an OIBD model of guinea pig. 
Methods
The ileal and distal colon muscle contraction in presence of different doses of DA-9701, morphine, and combination (morphine + DA-
9701) was measured by tissue bath study. The prokinetic effect of DA-9701 was assessed by charcoal transit and fecal pellet output 
assay in an OIBD model of guinea pig. 
Results
DA-9701 significantly increased the amplitude and area under the curve of ileal muscle contraction, while there was insignificant 
effect on the distal colon compared to the control. The maximal amplitude of ileal muscle contraction was acquired at a concentration 
of 10 μg/mL of DA-9701. In contrast, morphine significantly decreased the amplitude of ileal and distal colon muscle contraction 
compared to the control. Morphine delayed both upper (P < 0.01) and lower (P < 0.05) GI transit, and delayed GI transit was 
restored by the administration of DA-9701. Morphine induced reduction of contractility was significantly ameliorated by addition of 
DA-9701 in both ileal and distal colon muscles. 
Conclusions
DA-9701 significantly increased the amplitude of contraction of the ileal muscle, however the distal colon muscle contraction was 
insignificant. Additionally, it restored delayed upper and lower GI transit in an OIBD model of guinea pig, and it might prove to be a 
useful candidate drug in a clinical trial for OIBD. 
(J Neurogastroenterol Motil 2016;22:529-538)
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Introduction  
Morphine is an opioid analgesic drug and most commonly 
used in the treatment of malignant as well as functional and chronic 
gastrointestinal (GI) pain. Although opioids are globally prescribed 
by physicians as an analgesic, constipation is a common and persis-
tent side effect induced by this opioid.1,2 The constipation induced 
by opioids are commonly referred to as opioid induced bowel dys-
function (OIBD) and it has significant adverse effects on patient’s 
quality of life.3-5 The opioid induced constipation is predominantly 
mediated by gastrointestinal mu (μ) opioid receptors.6 High density 
μ opioid receptors are mostly found in neurons of myenteric, sub-
mucosal plexus, and the immune cells in lamina propria.7 Mor-
phine activates μ opioid receptors in the enteric nervous system, 
which in turn inhibits the normal release of excitatory and inhibi-
tory neurotransmitters that coordinates motility.5,8,9 Inhibition of 
excitatory neural pathways depresses peristaltic contractions, and on 
the other hand the blockade of inhibitory neural pathway increases 
GI muscle activity, elevates resting muscle tone, spasm and non-
propulsive motility patterns.5 Hence, μ receptor activation severely 
interrupts the rhythmic contractions and is responsible for delayed 
gastric emptying and slowing of the intestinal transit.8,9 Activation 
of opioid receptors inhibits water and electrolyte secretion into the 
gut lumen and increases fluid absorption from the intestine, and 
blood flow in the gut wall.10 As a result, the stool remains in the gut 
lumen for a longer time, therefore more fluid is reabsorbed and the 
stool becomes hard and dry.5,10 The above effects are also associated 
with opioid inhibition of secretomotor neurons in the epithelium of 
the gut. Firing of secretomotor neurons evokes secretion of H2O, 
electrolytes, and mucus. Morphine acts to hyperpolarize and silence 
action potential discharge by secretomotor neurons.9 The suppres-
sion of firing in the secretomotor neuronal pool reduces secretion, 
and results in lowered liquidity of small and large intestinal contents 
and drier harder stool in large intestine.11
There is currently no approved therapy in the specific manage-
ment of OIBD, though laxatives are the most commonly used. 
However, efficacy can be limited and most of them act slowly then 
abruptly, and also tolerability is poor which makes it difficult to 
control defecation in everyday life.12 Therefore, there is a need for 
a treatment regimen that has faster onset of action against opioid 
induced constipation than current laxatives. DA-9701 is a newly 
formulated prokinetic agent obtained from extracts of Pharbitis Se-
men and Corydalis Tuber.13-16 Both of these plants have been used 
in oriental traditional medicine for the treatment of GI disorders. 
Pharbitis Semen, the seed of Pharbitis nil Choisy, has been used as 
a folk medicine for its analgesic effects on abdominal disorders. Co-
rydalis Tuber, the root of Corydalis yahusuo W.T. Wang, has been 
used as a folk medicine for its analgesic and anti-ulcer effects.17-19 
DA-9701 has shown affinity for the dopamine (D)2, 5-hydroxy-
tryptamine (5-HT)4, 5-HT1A, and 5-HT1B receptors.
13,11,15 It has 
antagonistic effects on the D2 receptors and agonistic effects on the 
5-HT4, 5-HT1A and 5-HT1B receptors.
14,15,20 It has been reported 
that DA-9701 can improve delayed gastric emptying and may be 
effective as a prokinetic agent.14 Accordingly, DA-9701 is consid-
ered as a complex motility agent, which can be a solution to resolve 
the various symptoms of opioid induced constipation. Therefore, 
the aim of this study was to evaluate the effects of DA-9701, a novel 
prokinetic agent in the OIBD model of the guinea pig.
Materials and Methods  
Animals Handling and Preparation
Adult male Hartley guinea pigs (250-350 g, Orient Bio, Inc, 
Seoul, Korea) were acclimated to their holding room (temperature 
controlled at 21 ± 1oC, 50 ± 10% humidity, and 12-hour light/
dark cycle commencing at 7:00 AM) for at least a day prior to sur-
gery. The guinea pigs were deprived of food, but not water for a 24-
hour period before experiments. The guinea pigs were stunned by a 
blow on the head and exsanguinated by severing the carotid arteries 
just before the laparotomy to harvest segments of the ileum or dis-
tal colon. The ileum was harvested 5 cm proximally to the cecum, 
while the distal colon was harvested 5 cm proximal to the anus. 
All experiments were conducted in accordance with the Guide for 
the Care and Use of Laboratory Animals provided by the Animal 
Laboratory Ethics Committees of the Department of Laboratory 
Animal Medicine, Medical Research Center, Yonsei University 
College of Medicine. This study was approved by the institutional 
animal care and use committee (IACUC) of Yonsei University Col-
lege of Medicine with IRB protocol number 2013-0157.
Drugs
The following drugs and chemicals were used; charcoal (Sigma, 
St. Louis, MO, USA), barium sulfate (Tae Joon Pharmaceuticals, 
Seoul, Korea), and DA-9701 (Dong-A, Pharmaceuticals, Seoul, 
Korea), morphine (Myungmoon Pharm Co, Seoul, Korea). These 
were freshly prepared for every experiment by dissolving each com-
pound in isotonic sodium chloride solution.
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Experimental Design 1: Effect of DA-9701 on Ileal 
and Colonic Muscle Motor Function
Tissue bath study 
The ileal and distal colon muscle was removed and cut into 
3-mm wide and 10-mm long fragments and the lumen flushed 
clean using Krebs-Henseleit solution which was maintained at 
37oC, pH 7.4 and saturated with 95% O2 and 5% CO2 in a cham-
ber. The circular muscle was fixed and connected to independent 
tension transducers (BIOPAC TSD 105; BIOPAC Systems, Inc, 
Santa Barbara, CA, USA). The preparation was set up and al-
lowed to equilibrate for at least 60 minutes after 1 g resting tension. 
Circular muscle activity was quantified by means of a computerized 
integration procedure (BIOPAC MP 100; BIOPAC Systems, 
Inc). Drugs were added to the bath solution for 5 minutes without 
washing between successive changes in concentration. An indepen-
dent tissue bath study was performed using different concentrations 
of DA-9701 (1, 5, and 10 μg/mL) in order to analyze its effect on 
ileal and colonic muscle contraction. The maximal amplitude and 
area under the curves (AUC) of the ileal and distal colon muscle 
contraction were obtained to evaluate the effects of drugs on GI 
motility.
Experimental Design 2: Effect of Morphine on Ileal 
and Colonic Muscle Motor Function 
Tissue bath study
In order to create an experimental model of OIBD, different 
doses of morphine (0.1, 0.3, 1, 3, 10, and 30 μM) was examined 
for its effect on ileal and distal colon muscle contraction. The most 
effective dose concentration of morphine was selected to study the 
effect of DA-9701 in OIBD model.
Charcoal transit assay
The effect of morphine on upper GI transit was tested by the 
charcoal transit assay in fasted guinea pigs. Guinea pigs received 
a vehicle (0.9% normal saline) and different concentrations of 
morphine (0.3, 0.5, and 1 mg/kg) via an orogastric cannula. After 
30 minutes, vehicle (0.9% normal saline) was administered via the 
orogastric cannula, followed by 2.5 mL of a charcoal mixture after 
another 30 minutes wait. Upper GI transit was evaluated as the mi-
gration of charcoal mixture from the pylorus to the most distal point 
of migration, and expressed as a percentage (%) of charcoal migra-
tion (cm) to the length of total small intestine (cm) 10 minutes after 
injection of the charcoal mixture.
Fecal expulsion study
Similarly, the fecal pellet output assay was performed in order 
to test the effect of morphine on lower GI transit of the guinea pig. 
The fecal pellet output was measured in non-fasted guinea pigs 
receiving an intragastric administration of the vehicle (0.9% normal 
saline) and different concentrations of morphine (0.3, 0.5, and 1 
mg/kg). After 30 minutes, the vehicle (0.9% normal saline) was ad-
ministered via the orogastric cannula. Each guinea pig was placed 
into an individual experimental cage, and both weight and number 
of fecal pellets produced were measured and recorded. The result 
of 6 hours of cumulative fecal pellet output was measured for each 
guinea pig. 
Experimental Design 3: Effect of DA-9701 on 
Morphine Induced OIBD Model
Tissue bath study
The effect of different doses of DA-9701 (1, 5, 10, and 20 
μg/mL) in the presence of 1 μM morphine was recorded by a 
tissue bath study. 
Charcoal transit assay
The effect of DA-9701 on upper GI transit was tested by the 
charcoal transit assay in the morphine induced OIBD model of the 
guinea pig. Guinea pigs received vehicle (0.9% normal saline) and 
morphine 1 mg/kg via the orogastric cannula. After 30 minutes, 
vehicle (0.9% normal saline) and different doses of DA-9701 were 
administered via the orogastric cannula, followed by 2.5 mL of a 
charcoal mixture after another 30 minutes wait. Upper GI transit 
was evaluated in the same manner as mentioned above. 
Fecal expulsion study
The fecal pellet output assay was performed in order to test the 
effects of the prokinetic agent DA-9701 on lower GI transit in the 
morphine induced OIBD model. The fecal pellet output was mea-
sured in non-fasted guinea pigs receiving an intragastric administra-
tion of vehicle (0.9% normal saline) and morphine 0.3 mg/kg. After 
30 minutes, the vehicle (0.9% normal saline) and different doses of 
DA-9701 were administered via the orogastric cannula and fecal 
expulsion was measured in the same manner as mentioned above. 
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Statistical Methods
The results for each variable were expressed as a percentage of 
the control levels. Statistical analysis was performed using repeated 
measures ANOVA with post hoc comparison. In all test analyses, 
statistical significance was assigned if P < 0.05 based on the mean. 
Values are means with standard error. All data were analyzed using 
SPSS version 12.0 for Windows software (SPSS Inc, Chicago, IL, 
USA).
Results  
Effects of DA-9701 on Contraction of Ileal and 
Distal Colon Muscles
The degree of ileal muscle contraction was tested at differ-
ent doses of DA-9701. It significantly increased the amplitude of 
ileal muscle contraction in a dose dependent manner (1, 5, and 10 
μg/mL) compared to the control (Fig. 1A). At a concentration 
Figure 1. Effect of DA-9701 on contraction of the ileal muscle. DA-9701 increased maximal amplitude and area under the curve in a dose depen-
dent manner (1-10 μg/mL). (A) The percent change of amplitude from control (*P = 0.010). (B) The percent change of under the curve (AUC) 
from control (*P = 0.010) Values are represented in mean ± SEM.
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Figure 2. Effect of DA-9701 on contraction of the distal colon muscle. DA-9701 increased amplitude and under the curve (AUC) compared to 
that of control. Values are represented in mean ± SEM.
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of 10 μg/mL of DA-9701, the amplitude of the contraction was 
maximal (P = 0.010). As shown in Figure 1B, AUC of the ileal 
muscle contraction also significantly increased in a dose dependent 
manner with the highest peak recorded at 10 μg/mL of DA-9701. 
Similarly, we tested the effects of DA-9701 on the contraction of 
the distal colon muscle. However, there was insignificant increase 
in the amplitude and AUC in the presence of different doses of 
DA-9701 as compared to the control (Fig. 2). 
Effect of Morphine on Contraction of Ileal and 
Distal Colon Muscle
In order to generate an OIBD model, we tested the effect of 
different concentrations of morphine on the amplitude of contrac-
tion in the ileal and distal colon muscles. As shown in Figure 3A, 
out of 6 different doses of morphine analyzed in this study, 1, 3, and 
10 μM significantly decreased the amplitude of the contraction in 
the ileal muscle compared to the control (P = 0.010). The ampli-
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Figure 3. Effects of morphine on contraction of the ileal muscle. Morphine decreased maximal amplitude and area under the curve (AUC). (A) 
Percent change of amplitude from control (*P = 0.010). (B) Percent change of AUC from control. Values are represented in mean ± SEM.
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Figure 4. Effects of Morphine on contraction of the distal colon muscle. Morphine decreased maximal amplitude and area under the curve (AUC). 
(A) Percent change of amplitude from control (*P = 0.010). (B) Percent change of AUC from control (*P = 0.010) Values are represented in 
mean ± SEM.
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tude of ileal muscle contractions were 45.35 ± 33.64%, 45.11 ± 
36.86%, 45.57 ± 39.75% in the presence of 1, 3, and 10 μM mor-
phine respectively. In contrast, there was no change in AUC at any 
dose of the morphine treatment on the ileal muscle (Fig. 3B). In the 
distal colon muscle, morphine exerts a similar effect on the ampli-
tude as that of the ileal muscle. The doses of 1, 3, and 10 μM had 
respective amplitude values of 41.23 ± 12.49%, 42.97 ± 11.06%, 
and 43.58 ± 9.60% respectively, and hence significant decrease 
from the control (Fig. 4A). Similarly, the AUC of the distal colon 
also significantly decreased at doses of 1, 3, and 10 μM (Fig. 4B). 
Effect of Different Doses of Morphine on Upper and 
Lower Gastrointestinal Transit 
Three different doses (0.3, 0.5, and 1 mg/kg) of morphine 
were tested in upper and lower GI transit experiments in order to 
select the most effective dose for creation of an OIBD model. As 
shown in Figure 5, the percentage charcoal transit (cm/cm × 100) 
in the control group was 65.57 ± 10.83, while those in the 0.3, 0.5, 
and 1 mg/kg morphine treated groups were 48.03 ± 9.87, 38.45 ± 
9.20, and 12.72 ± 13.21% respectively. Among the 3 doses tested, 
dose 1 mg/kg morphine most significantly delayed the charcoal 
transit in the upper GI tract compared to the control. In the lower 
GI transit assay the number of fecal pellets expelled in the control 
group was 15.22 ± 15.78, while those in the 0.3, 0.5, and 1 mg/kg 
morphine treated groups were 8.00 ± 6.78, 12.16 ± 10.55, and 
12.66 ± 10.83 respectively. The comparison of the control group 
with morphine treated groups clearly showed that the dose 0.3 mg/
kg of morphine significantly decreased the cumulative number of 
fecal pellet output expelled compared to the control (Fig. 6). 
Effects of DA-9701 on Morphine Treated Ileal and 
Distal Colon Muscle
Following testing of the effects of morphine on ileal and distal 
colon contractility, we selected 1 μM morphine as a base dose to 
analyze DA-9701 prokinetic effects. As shown in Figure 7A, the 
addition of DA-9701 to base dose 1 μM morphine treated ileum 
increased the amplitude of contraction in a dose dependent manner 
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(1-20 μg/mL). Ten and 20 μg/mL  DA-9701 concentrations sig-
nificantly restored the amplitude and AUC of ileal muscles treated 
with morphine 1 μM (Fig. 7). Similarly,  DA-9701 also restored 
the amplitude of distal colon contraction and AUC in a dose de-
pendent manner (1-20 μg/mL) (Fig. 8). Unlike the ileal muscle, 
the distal colon showed significantly high contraction only at the 
maximal concentration.
Effects of DA-9701 on the Charcoal Transit in 
Opioid Induced Bowel Dysfunction Model
The most effective dose of morphine (1 mg/kg) was selected in 
order to induce the experimental model of the OIBD in the guinea 
pig. The prokinetic effect of different doses (1, 3, and 10 mg/kg) of 
DA-9701 on the upper GI transit was tested in the OIBD model. 
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As shown in Figure 9, the administration of 3 mg/kg and 10 mg/
kg of DA-9701 in morphine induced OIBD cases significantly 
increased the charcoal transit (12.72 ± 13.21 vs 24.99 ± 8.20) and 
(12.72 ± 13.21 vs 23.25 ± 12.52), respectively (Fig. 9). Hence, 
DA-9701 significantly reversed abnormally delayed upper GI tran-
sit induced by morphine. 
Effects of DA-9701 on Fecal Expulsion in Opioid 
Induced Bowel Dysfunction Model
In the fecal expulsion assay the most effective dose of morphine 
(0.3 mg/kg) was selected to induce the experimental model of the 
OIBD in the guinea pig. The prokinetic effect of different doses 
(1, 3, and 10 mg/kg) of DA-9701 on the lower GI transit was 
tested in the OIBD model. As shown in Figure 10, the cumulative 
fecal pellet output and cumulative fecal pellet output weight (g) 
significantly increased in presence of all 3 doses of DA-9701. These 
results showed that DA-9701 significantly restored lower GI transit 
induced by morphine. 
Discussion  
Opioid induced bowel dysfunction (OIBD) is associated with 
adverse effect of opioid analgesics on μ-opioid receptors located in 
the enteric nervous system. Opioid activated μ-receptors disrupt GI 
function that leads to delayed gastric emptying, infrequent bowel 
movements and difficulty in rectal expulsion of stool. Webster et 
al21 hypothesized the action of alvimopan as selective antagonism of 
peripheral μ-opioid receptors that leads to restoration of GI func-
tion and relieve opioid induced bowel dysfunction. Most of the 
studies suggested the activation of opioid receptors in the GI tract 
as a major cause of OIBD.8,9 Several prokinetic agents have been 
developed recently, yet their use is restricted due to serious side ef-
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Figure 9. The effect of DA-9701 on upper gastrointestinal transit in 
opioid induced bowel dysfunction guinea pig model. Values are mean 
± SEM. *P < 0.05 and **P < 0.01 in comparison to morphine only. 
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fects and failure to confirm their efficacy. On the other hand Sloots 
et al22 studied the efficacy and safety of prucalopride in chronic 
constipation from opioid induced constipation, and they suggested 
improved bowel movement frequency. Hence, there is an increasing 
challenge to develop safer and more effective therapeutic agents for 
the treatment of OIBD. In this series, we have tested a newly for-
mulated prokinetic agent called DA-9701, and its pharmacological 
effects on OIBD induced GI motor dysfunction. Our current study 
clearly demonstrated the promising effects of DA-9701 on enhanc-
ing GI motor function as evaluated by ileal and distal colon muscle 
contraction and GI transit. DA-9701 augments the amplitude of 
contraction of normal ileal muscle. The amplitude of contraction 
of the distal colon muscle was not significantly increased as that of 
the ileum. This suggests that the prokinetic effect of DA-9701 on 
the small intestine was greater than that of the distal large intestine. 
Our findings corroborate with a previous animal study in which 
DA-9701 significantly accelerated gastric emptying in normal rats, 
as well as in abnormally-induced conditions such as delayed gastric 
emptying caused by apomorphine, a dopamine agonist.14 Further-
more, DA-9701 also significantly improved gastric compliance in 
canines.15 
Our study showed that morphine induces differential dose de-
pendent inhibition of the upper and lower GI motility. The differ-
ential action of morphine in the GI tract can be partially explained 
by opioid receptor distribution, receptor density, and tissue specific 
localization. Hence, we speculate major differences in opioid recep-
tor distribution within the upper and lower GI tract, and hence 
morphine can act differently in receptor binding, opioid specific 
signal transduction pathways and receptor desensitization. More 
studies are warranted in order to ascertain the distribution and exact 
localization of the opioid receptors. Additionally, the effect of DA-
9701 on GI transit in morphine OIBD was determined by charcoal 
transit and fecal pellet output assays. The oral administration of 
DA-9701 in the preclinical OIBD model, significantly reversed the 
GI inhibitory effects of morphine and restored the delayed upper 
and lower GI transit. These result showed the remarkable proki-
netic properties of DA-9701 that could enhance GI motility both in 
normal and abnormal conditions. Therefore, the pharmacological 
action and affinity of DA-9701 need to be addressed in OIBD. 
The novel prokinetic agent DA-9701 exerts a prokinetic effect 
in the OIBD model of the guinea pig. It clearly increased the ileal 
and distal colon muscle contraction and improved gastrointestinal 
transit in OIBD. This drug may serve as a useful candidate drug in 
a clinical trial for OIBD. 
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